Akari Therapeutics 'encouraged' by new Coversin data
Akari Therapeutics announced recent developments and supporting data which underscore the differentiation of Coversin. "We are encouraged by new data that demonstrates the potential for improved patient comfort and ease of use. Alongside this focus on patient convenience we continue to develop Coversin as a differentiated treatment by means of its combined complement C5 and LTB4 inhibitory activity with early data readouts of our bullous pemphigoid and atopic keratoconjunctivitis trials expected in first quarter 2019," said Clive Richardson, Interim Chief Executive Officer of Akari Therapeutics. New data showing Coversin can be concentrated to 150mg/ml at low viscosity validates the enhanced convenience of the auto-injector pen across Akari subcutaneous program - currently PNH, thrombotic microangiopathy and BP. New highly concentrated formulation with small volume and water-like viscosity allows ease of administration and increasing patient comfort. Single cartridge to contain seven days of dosing which is stable at room temperature allowing patients to carry drug with them. A second eculizumab-resistant patient with PNH has now received more than six months of Coversin therapy treatment. Resistant to eculizumab because of a known C5 polymorphism. Previously transfusion-dependent and has now been transfusion independent for five months. New pharmacokinetic data for PAS Coversin supports once weekly dosing. Preclinical data investigating the half-life of PAS Coversin in three species supports potential for once weekly dosing in man.